vs
Side-by-side financial comparison of Good Times Restaurants Inc. (GTIM) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Good Times Restaurants Inc. is the larger business by last-quarter revenue ($32.7M vs $18.6M, roughly 1.8× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 0.6%, a 65.2% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -10.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -0.7%).
Good Times is a Golden, Colorado–based fast-food restaurant specializing in premium burgers and frozen custard. As of July 2023, the chain operates 31 locations, down from 38 in 2015.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
GTIM vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.7M | $18.6M |
| Net Profit | $181.0K | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 0.9% | 56.3% |
| Net Margin | 0.6% | 65.7% |
| Revenue YoY | -10.0% | 1808.5% |
| Net Profit YoY | 10.4% | 376.5% |
| EPS (diluted) | $0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.7M | $18.6M | ||
| Q3 25 | $37.0M | $334.0K | ||
| Q2 25 | $34.3M | $1.4M | ||
| Q1 25 | — | $257.0K | ||
| Q4 24 | $36.3M | $977.0K | ||
| Q3 24 | $35.8M | $660.0K | ||
| Q2 24 | $38.0M | $736.0K | ||
| Q1 24 | $35.4M | $1.4M |
| Q4 25 | $181.0K | $12.3M | ||
| Q3 25 | $1.5M | $-8.6M | ||
| Q2 25 | $-624.0K | $-6.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $164.0K | — | ||
| Q3 24 | $230.0K | $-2.8M | ||
| Q2 24 | $1.3M | $-14.5M | ||
| Q1 24 | $618.0K | $411.0K |
| Q4 25 | 0.9% | 56.3% | ||
| Q3 25 | 3.3% | -2516.5% | ||
| Q2 25 | -1.5% | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | -0.3% | -1563.6% | ||
| Q2 24 | 3.2% | -1255.0% | ||
| Q1 24 | 1.8% | -692.5% |
| Q4 25 | 0.6% | 65.7% | ||
| Q3 25 | 4.0% | -2572.2% | ||
| Q2 25 | -1.8% | -504.8% | ||
| Q1 25 | — | -2097.7% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.6% | -425.5% | ||
| Q2 24 | 3.5% | -1964.4% | ||
| Q1 24 | 1.7% | 29.9% |
| Q4 25 | $0.02 | $0.25 | ||
| Q3 25 | $0.14 | $-0.17 | ||
| Q2 25 | $-0.06 | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.01 | $-0.06 | ||
| Q2 24 | $0.12 | $-0.30 | ||
| Q1 24 | $0.06 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $33.2M | $49.4M |
| Total Assets | $82.5M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | $2.7M | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | $3.0M | $59.3M | ||
| Q3 24 | $3.9M | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | $4.0M | $80.2M |
| Q4 25 | $33.2M | $49.4M | ||
| Q3 25 | $33.1M | $36.4M | ||
| Q2 25 | $31.6M | $44.5M | ||
| Q1 25 | — | $50.5M | ||
| Q4 24 | $32.4M | $55.1M | ||
| Q3 24 | $32.4M | $58.5M | ||
| Q2 24 | $32.3M | $60.4M | ||
| Q1 24 | $31.6M | $74.1M |
| Q4 25 | $82.5M | $59.0M | ||
| Q3 25 | $85.8M | $51.1M | ||
| Q2 25 | $86.9M | $60.7M | ||
| Q1 25 | — | $67.9M | ||
| Q4 24 | $89.5M | $90.6M | ||
| Q3 24 | $87.1M | $99.0M | ||
| Q2 24 | $90.1M | $107.8M | ||
| Q1 24 | $89.0M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.4M | $18.4M |
| Free Cash FlowOCF − Capex | $1.2M | — |
| FCF MarginFCF / Revenue | 3.8% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 7.85× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-72.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4M | $18.4M | ||
| Q3 25 | $1.3M | $-8.7M | ||
| Q2 25 | $714.0K | $-7.5M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | $-518.0K | $-24.0M | ||
| Q3 24 | $394.0K | $765.0K | ||
| Q2 24 | $3.2M | $-10.9M | ||
| Q1 24 | $1.8M | $-4.0M |
| Q4 25 | $1.2M | — | ||
| Q3 25 | $735.0K | — | ||
| Q2 25 | $-105.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-466.0K | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $1.2M | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -1.3% | — | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | 7.85× | 1.50× | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.16× | — | ||
| Q3 24 | 1.71× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 2.86× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GTIM
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
